{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-255083","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2023-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.094205+00:00","generated_at":"2026-06-10T00:49:45.021685+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PMV Pharma: PC14586 Phase 1 shows 38% ORR at RP2D; registrational Phase 2 planned early 2024","bullets":["Confirmed ORR 38% (6/16) at RP2D 2000 mg daily in TP53 Y220C/KRAS wild-type patients; median DoR 7 months.","Responses across ovarian, breast, prostate, lung, endometrial cancers; 34% ORR in efficacious dose range (13/38).","Well tolerated: most TRAEs Grade 1-2 (nausea, vomiting, creatinine increase); only 3% discontinuation due to TRAE.","RP2D selected after End of Phase 1 meeting with FDA in Q3 2023; Phase 2 registrational trial to start early 2024.","Study enrolled heavily pretreated patients (median 3 prior lines); no approved therapies targeting p53 currently exist."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-255083","json":"https://secwatch.observer/filing/0001193125-23-255083.json","markdown":"https://secwatch.observer/filing/0001193125-23-255083.md","text":"https://secwatch.observer/filing/0001193125-23-255083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000119312523255083/0001193125-23-255083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000119312523255083/d534012d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T00:49:45.021685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}